Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NSI 566

Drug Profile

NSI 566

Alternative Names: hCNS-SC - Seneca Biopharma; HuCNS-SC - Seneca Biopharma; Neural Stem Cells - Seneca Biopharma; NSI-566; NSI-566RSC

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuralstem
  • Developer CJ HealthCare; Emory University; Neuralstem China; Seneca Biopharma; University of California, San Diego; University of Freiburg
  • Class Antidementias; Antiparkinsonians; Eye disorder therapies; Neuroprotectants; Nootropics; Stem cell therapies
  • Mechanism of Action Cell replacements; Neurogenesis stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Stroke
  • Phase II Amyotrophic lateral sclerosis
  • Phase I Spinal cord injuries
  • No development reported Alzheimer's disease; Brain injuries; Cerebral palsy; Cognition disorders; Diabetic neuropathies; Huntington's disease; Lysosomal storage diseases; Multiple sclerosis; Optic neuritis; Paraplegia; Parkinson's disease

Most Recent Events

  • 28 Oct 2019 Neuralstem is now called Seneca Biopharma
  • 24 Sep 2019 Neuralstem completes enrolment in its phase II trial in ischaemic Stroke trial in China
  • 01 Jul 2019 Efficacy and adverse events data from a phase I trial in Stroke released by Neuralstem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top